BSD Medical announces results from BSD-2000 hyperthermia system study on pancreatic cancer

Published on February 6, 2013 at 3:14 AM · No Comments

BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced the publication of results from a clinical study on advanced pancreatic cancer using the BSD-2000 Hyperthermia System (BSD-2000). The study, "Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer", (Int J Hyperthermia. 2013;29[1]:8-16) reported the results of a retrospective analysis of 23 patients with advanced or metastatic pancreatic cancer who had relapsed after first-line chemotherapy treatment. The researchers, Tschoep-Lechner, et al., reported that hyperthermia, delivered using the BSD-2000, combined with gemcitabine and cisplatin resulted in low toxicity and high feasibility, even in these study patients who had a very negative prognosis and no standard treatment options. The researchers also reported that, despite the intrinsic limitation of a small retrospective analysis, the results suggested clinical efficacy of hyperthermia combined with gemcitabine and cisplatin whereas gemcitabine and cisplatin without hyperthermia does not seem to provide a significant benefit in patients with advanced pancreatic cancer.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post